- Conditions
- Uterine Fibroids, Polyps
- Interventions
- MyoSure Tissue Removal System
- Device
- Lead sponsor
- Hologic, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 290 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2013
- U.S. locations
- 1
- States / cities
- Marlborough, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 121–144
of 160
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Uterine Fibroids - 1St Diagnosis, Uterine Fibroids Affecting Pregnancy, Uterine Fibroid Degenerated
- Interventions
- Holistic Medicine (HM)
- Behavioral
- Lead sponsor
- Virtual Tribunal Monastery
- Other
- Eligibility
- 22 Years and older · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- Anchorage, Alaska
- Conditions
- Leiomyoma, Leiomyomatosis, Uterine Neoplasms
- Interventions
- Uterine fibroid embolization BeadBlock™, Uterine fibroid embolization Embosphere®
- Device
- Lead sponsor
- Worthington-Kirsch, Robert L., M.D.
- Individual
- Eligibility
- 30 Years to 50 Years · Female only
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2010
- U.S. locations
- 2
- States / cities
- Albany, New York • Pottstown, Pennsylvania
- Conditions
- Uterine Fibroids
- Interventions
- Placebo, Telapristone Acetate
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 47 Years · Female only
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 8
- States / cities
- Fort Lauderdale, Florida • Sandy Springs, Georgia • Metairie, Louisiana + 4 more
- Conditions
- Leiomyoma
- Interventions
- Hysterectomy, Myomectomy, Uterine Fibroid Embolization
- Procedure
- Lead sponsor
- U.S. Army Medical Research and Development Command
- Federal
- Eligibility
- 35 Years to 50 Years · Female only
- Enrollment
- 400 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2005 – 2010
- U.S. locations
- 4
- States / cities
- Washington D.C., District of Columbia • Cleveland, Ohio • Pittsburgh, Pennsylvania
- Conditions
- Leiomyoma
- Interventions
- ExAblate 2000
- Device
- Lead sponsor
- InSightec
- Industry
- Eligibility
- Female only
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Uterine Fibroids
- Interventions
- Proellex 25 mg, Proellex 50 mg, Lupron Depot
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 3
- States / cities
- Sarasota, Florida • Houston, Texas
- Conditions
- Urinary Tract Infection, Leiomyoma
- Interventions
- Not listed
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 860 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Uterine Bleeding, Uterine Fibroids, Adenomyosis
- Interventions
- Evaluation of MRI, US for pelvic and uterine conditions, Patient preference between MRI and Ultrasound
- Procedure
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Fibroid Uterus, Fibroid Tumor, Leiomyoma, Fibromyoma, Leiomyoma, Uterine
- Interventions
- Simvastatin 40mg, Placebo 40 mg
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2026
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Fibroid
- Interventions
- PRA-027
- Drug
- Lead sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Industry
- Eligibility
- 18 Years to 60 Years · Female only
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Heavy Menstrual Bleeding, Uterine Fibroids
- Interventions
- Elagolix, Estradiol /norethindrone acetate (E2/NETA), E2/NETA Placebo, Elagolix Placebo
- Drug · Other
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 478 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2024
- U.S. locations
- 155
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Fairhope, Alabama + 112 more
- Conditions
- Fallopian Tube Patency Tests, Fibroid/Myoma (Uterus/Cervix), Myomectomy, Fallopian Tube Disease
- Interventions
- chromopertubation
- Procedure
- Lead sponsor
- Medstar Health Research Institute
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Washington D.C., District of Columbia
- Conditions
- Fibroid Uterus
- Interventions
- Bupivacaine, Bupivacaine liposome, normal saline
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years to 64 Years · Female only
- Enrollment
- 140 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Menorrhagia, Uterine Fibroids
- Interventions
- Doppler-Guided Uterine Artery Occlusion Device (DUAO)
- Device
- Lead sponsor
- Ethicon, Inc.
- Industry
- Eligibility
- 25 Years to 50 Years · Female only
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2010
- U.S. locations
- 9
- States / cities
- Phoenix, Arizona • Fort Lauderdale, Florida • Southfield, Michigan + 6 more
- Conditions
- Leiomyoma, Laparoscopy, Uterine Myomectomy
- Interventions
- Standard, Standard-vaginal misoprostol
- Drug
- Lead sponsor
- Antonios Likourezos
- Other
- Eligibility
- 18 Years to 55 Years · Female only
- Enrollment
- 74 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Brooklyn, New York
- Conditions
- Uterine Bleeding, Decision Aid
- Interventions
- Video on uterine fibroids
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Uterine Leiomyomas, Fibroids, Uterine Fibroids, Myomas
- Interventions
- DNA analysis, Hormonal analysis
- Genetic · Other
- Lead sponsor
- Elizabeth A. Stewart
- Other
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 38 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2009 – 2015
- U.S. locations
- 1
- States / cities
- Rochester, Minnesota
- Conditions
- Pelvic Organ Prolapse, Gynecologic Cancers, Uterine Leiomyomata, Adenomyosis, Endometrial Hyperplasia, Other Abnormal Uterine and Vaginal Bleeding, Pelvic Mass, Pelvic Pain
- Interventions
- Not listed
- Lead sponsor
- University of South Florida
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2016
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Uterine Fibroids (UF), Menstrual Disorders, Adenomyosis of Uterus, Endometriosis, Uterine Prolapse, Precancerous/Nonmalignant Condition, Cervical Cancer, Endometrial Cancer, Ovarian Cancer
- Interventions
- Robotic Assisted-Surgery (RAS) Hysterectomy
- Device
- Lead sponsor
- Medtronic - MITG
- Industry
- Eligibility
- 22 Years and older · Female only
- Enrollment
- 70 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2031
- U.S. locations
- 5
- States / cities
- Jacksonville, Florida • Tampa, Florida • Durham, North Carolina + 2 more
- Conditions
- Uterine Fibroids
- Interventions
- Embozene® Microspheres, Embosphere®
- Device
- Lead sponsor
- Boston Scientific Corporation
- Industry
- Eligibility
- 30 Years to 50 Years · Female only
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 2
- States / cities
- Albany, New York • New Hyde Park, New York
- Conditions
- Uterine Leiomyoma
- Interventions
- Not listed
- Lead sponsor
- National Institute of Environmental Health Sciences (NIEHS)
- NIH
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 374 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2019
- U.S. locations
- 1
- States / cities
- Research Triangle Park, North Carolina
- Conditions
- Dysmenorrhea (Disorder), Dysmenorrhea Primary, Dysmenorrhea Secondary, Endometrial Diseases, Leiomyoma, Fibroid Uterus
- Interventions
- Naproxen Sodium, Placebo
- Drug
- Lead sponsor
- Endeavor Health
- Other
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 183 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Evanston, Illinois
- Conditions
- Leiomyoma, Uterine Hemorrhage
- Interventions
- Ulipristal acetate (UPA), Placebo
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 50 Years · Female only
- Enrollment
- 157 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 28
- States / cities
- Tucson, Arizona • San Diego, California • Denver, Colorado + 23 more